Amitkumar N. Mehta

Hematology

1720 2nd Ave S
Birmingham, AL 35294

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal

Published: December 12, 2025

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Journal: Future oncology (London, England)

Published: December 10, 2025

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Journal: British journal of haematology

Published: October 17, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances

Published: September 24, 2025

A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Journal: Blood cancer discovery

Published: August 27, 2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Journal: Blood

Published: February 18, 2025

Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.

Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.

Journal: Journal of the American Academy of Dermatology

Published: January 16, 2025

Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.

Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 18, 2024

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.

Journal: Bone marrow transplantation

Published: November 17, 2024

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.

Journal: Blood advances

Published: September 24, 2024

Showing 1-12 of 82

Last Updated: 09/26/2026